Interferon gamma News and Research

RSS

Frequency and function of SARS-CoV-2-specific T cells in individuals with pulmonary PASC

Researchers examined patients with pulmonary PASC of SARS-CoV-2 to determine the frequency and function of SARS-CoV-2-specific T cells in their blood.

17 Feb 2022

The long-term consequences of SARS-CoV-2 infection in people with HIV

In a recent study posted to the medRxiv* preprint server, an interdisciplinary team of researchers from the United States (US) analyzed a cohort of patients with human immunodeficiency virus (HIV) (PWH) recovering from coronavirus disease 2019 (COVID-19) and characterized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific immune responses in these patients.

15 Feb 2022

Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity

In a new study, researchers investigated whether neutralizing antibodies against the SARS-CoV-2 spike protein offered adequate immunity against breakthrough infections among vaccinated individuals.

15 Feb 2022

Measuring T cell responses to SARS-CoV-2 vaccination and infection in healthcare workers with two different assays

The purpose of this study was to compare the OI TSPOT with the in-house PITCH ELISpot for reporting T cell responses specific to SARS-CoV-2 spike and structural proteins.

10 Feb 2022

Impact of genetic changes in Omicron variant on an immunodominant T-cell epitope

Researchers describe the impact of changes in the Omicron variant on a uniquely immunodominant spike-encoded CD8+ T-cell epitope.

9 Feb 2022

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

A team of scientists from the United States has recently demonstrated that current coronavirus disease 2019 (COVID-19) vaccines induce robust spike-specific T cell responses against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Feb 2022

Vaccine-induced immunological memory is similar for Omicron and Delta SARS-CoV-2 variants

A new study by Norwegian researchers suggests that vaccine-induced immunological memory and the activation of recall responses in the body yields similar coverage for Omicron and Delta variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

31 Jan 2022

Imaging microscopy shows killer T-cells targeting SARS-CoV-2 spike protein

Researchers demonstrate how cytotoxic T-lymphocytes (CTLs) with specificity for SARS-CoV-2 eliminate multiple infected targets.

30 Jan 2022

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Researchers describe the state of adaptive immunity following vaccination with the Pfizer-BioNTech BNT162b2 COVID-19 vaccine.

23 Jan 2022

A common cold may boost the immune system against COVID-19

A recent groundbreaking research paper published in the journal Nature Communications reveals the association of circulating SARS-CoV-2-specific T cells at exposure with lack of infection – implying the protective role for cross-reactive immune T cells in coronavirus disease 2019 (COVID-19) and opening the door for second-generation vaccines that could circumvent spike-antibody immune escape variants.

11 Jan 2022

Study finds heterologous vaccine booster evokes robust immunity to SARS-CoV-2 Omicron variant

The current study examines the role of heterologous vaccination, an area that lacks much clarity.

11 Jan 2022

Immunological factors associated with impaired BNT162b2 mRNA vaccine response in older adults

A new study posted to the pre-print server medRxiv* investigated the significant immune alterations concerning SARS-CoV-2 specific innate and adaptive immunity associated with a lower BNT162b2 mRNA vaccine response in older individuals.

10 Jan 2022

Oral bacteria-based SARS-CoV-2 vaccine platform

In a new study, researchers engineered the bacterial strain, Salmonella, to express differently-sized antigens to serve as vaccine platforms.

5 Jan 2022

Transcription factor Blimp1 identified as potential target for modulating T-reg activity to treat cancer

In cancer, a major obstacle to anti-tumor immunity and immunotherapy treatment is the infiltration of regulatory T cells, or T-reg cells, into a tumor. These immune cells generally turn down the immune response, and they can prevent the immune system from destroying cancer cells.

22 Dec 2021

Impact of acute kidney injury associated gene expression in human kidney cells

A new study attempts to perform a comparative single-cell census of human kidneys employing samples from individuals suffering from acute kidney injury and controls without the condition.

20 Dec 2021

Determination of the effectiveness of COVID-19 vaccination using T cell receptor repertoire

A new study published on the bioRxiv preprint server has hypothesized that T cell receptors (TCR) repertoire can measure the response to vaccines, as it would identify the TCR of clones that respond to the vaccination.

13 Dec 2021

Immune response of Pfizer vaccinees who received Moderna or Pfizer booster

A new preprint discusses the immune boost resulting from homologous or heterologous booster doses in individuals fully vaccinated with two doses of the Pfizer vaccine.

7 Dec 2021

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

In a recent study conducted at Yale University, USA, scientists have investigated the immunogenicity of mRNA-based coronavirus disease 2019 (COVID-19) vaccine candidates encoding the spike proteins of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The findings reveal that the vaccines induce robust immune responses against SARS-CoV-2 variants. The study is currently available on the bioRxiv* preprint server.

6 Dec 2021

Safety and immunogenicity of different COVID-19 booster vaccines

New study findings suggest that booster vaccination with an mRNA-based vaccine has the highest immunogenicity against the COVID-19 Delta variant.

1 Dec 2021

NIH study finds naturally acquired immunity is weak against SARS-CoV-2 variants

Immunity acquired after recovering from SARS-CoV-2 infection is not sufficient in protecting against reinfection from variants.

18 Nov 2021